Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess if treatment with IDO/Survivin peptide vaccine can enhance
the efficacy of temozolomide chemotherapy in patients with metastatic malignant melanoma.